Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
Martin, Claire. A; Cullinane, C; Kirby, Laura; Abuhammad, Shatha; Lelliott, Emily.J; Waldeck, Kelly; Young, Richard J.; Brajanovski, Natalie; Cameron, Donald; Walker, Rachael; Sanij, Elaine; Poortinga, Gretchen; Hannan, Ross; Pearson, Richard B; Hicks, Rodney J.; McArthur, Grant; Sheppard, Karen E.
Increased CDK4 activity occurs in the majority of melanomas and CDK4/6 inhibitors in combination with BRAF and MEK inhibitors are currently in clinical trials for the treatment of melanoma. We hypothesize that the timing of the addition of CDK4/6 inhibitors to the current BRAF and MEK inhibitor regime will impact on the efficacy of this triplet drug combination. The efficacy of BRAF, MEK and CDK4/6 inhibitors as single agents and in combination was assessed in human BRAF mutant cell lines that...[Show more]
|Collections||ANU Research Publications|
|Source:||International Journal of Cancer|
|01_Martin_Palbociclib_synergizes_with_2018.pdf||1.02 MB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.